Drugs

, Volume 58, Supplement 2, pp 37–42 | Cite as

Toxicity of Quinolones

  • Ralf Stahlmann
  • Hartmut Lode
Oral Presentations Review Article

Abstract

Reactions of the gastrointestinal tract, the CNS and the skin are the most often observed adverse effects during therapy with fluoroquinolones. At least for some of the newer fluoroquinolones a steep dose-response relationship of adverse effects seems to exist. Pathogenesis of the neurotoxic effects of fluoroquinolones is still unknown. Among the newer drugs, trovafloxacin caused mild CNS reactions such as dizziness and lightheadedness in a considerable proportion of patients. Young females seem to be especially sensitive to this effect, which diminishes during treatment or if taken together with food. Cardiotoxic potentials of sparfloxacin and grepafloxacin are higher than those of other fluoroquinolones, but during therapy no clearcut drug-related serious reactions have been reported, apart from a slight prolongation of the QT interval. However, to avoid risks these drugs should not be prescribed to patients with known prolongation of the QT interval (e.g. patients on antiarrhythmics).

Phototoxicity has been described for all quinolones, but derivatives with a halogen atom at position 8 show the highest potential for such reactions. Fleroxacin, sparfloxacin, clinafloxacin and lomefloxacin belong to this group of fluoroquinolones. The phototoxic potential of the other new fluoroquinolones is considerably lower, but extensive exposure to UV light should generally be avoided during therapy with all quinolones.

Chondrotoxicity of quinolones, as observed in immature animals, can affect articular cartilage and/or the epiphyseal growth plate, depending on the developmental stage. Pathogenesis of chondrotoxicity can probably be explained by the magnesium-chelating properties of these drugs. As juveniles are especially sensitive, use of these drugs in paediatrics should be restricted to carefully selected indications (such as the use of ciprofloxacin in cystic fibrosis).

Another manifestation of the toxic effects of quinolones on connective tissue structures are tendopathies. Tendinitis and tendon ruptures have occurred as late as several months after quinolone treatment.

Overall, quinolones are well tolerated drugs. Their specific toxic potentials have to be considered when they are chosen for treatment of bacterial infections.

Keywords

Fluoroquinolones Ofloxacin Quinolones Moxifloxacin Antimicrob Agent 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Stahlmann R, Lode H. Safety overview. Toxicity, adverse effects, and drug interactions. In: Andriole VT, editor. The Quinolones, 2nd ed. San Diego, California: Academic Press, 1998: 369–415Google Scholar
  2. 2.
    Kawai Y, Matsubayashi K, Hakusui H. Interaction of quinolones with metal cations in aqueous solution. Chem Pharm Bull 1996; 44: 1425–30CrossRefGoogle Scholar
  3. 3.
    Palù G, Valisena S, Ciarrocchi G, et al. Quinolone binding to DNA is mediated by magnesium ions. Proc Natl Acad Sci USA 1992; 89: 9671–5PubMedCrossRefGoogle Scholar
  4. 4.
    Lode H. Drug interactions with quinolones. Rev Infect Dis 1988; 10 Suppl. 1: S132–6PubMedCrossRefGoogle Scholar
  5. 5.
    Höffken G, Lode H, Wiley R, et al. Pharmacokinetics and bioavailability of ciprofloxacin and ofloxacin, effect of food and antacid intake. Rev Infect Dis 1988; 10 Suppl. 1: 138–9CrossRefGoogle Scholar
  6. 6.
    Stahlmann R, Vormann J, Günther T, et al. Effects of quinolones, magnesium deficiency or zinc deficiency on joint cartilage in rats. Magn Bull 1997; 19: 7–22Google Scholar
  7. 7.
    Stahlmann R. Safety profile of the quinolones. J Antimicrob Chemother 1990; 26 Suppl. D: 31–44PubMedCrossRefGoogle Scholar
  8. 8.
    Norrby SR, Lietman PS. Safety and tolerability of fluoroquinolones. Drugs 1993; 45 Suppl. 3: 59–64PubMedCrossRefGoogle Scholar
  9. 9.
    Christ W, Esch B. Adverse reactions to fluoroquinolones in adults and children. Infect Dis Clin Pract 1994; 3 Suppl. 3: S168–76CrossRefGoogle Scholar
  10. 10.
    Stahlmann R, Schwabe R. Safety profile of grepafloxacin as compared with other fluoroquinolones. J Antimicrob Chemother 1997; 40 Suppl. A: 83–92PubMedCrossRefGoogle Scholar
  11. 11.
    Lipsky BA, Baker CA. Fluoroquinolone toxicity profiles: a review focusing on newer agents. Clin Infect Dis 1999; 28: 352–64PubMedCrossRefGoogle Scholar
  12. 12.
    Langan CE, Cranfield R, Breisch S, et al. Randomized, double-blind study of grepafloxacin versus amoxycillin in patients with acute bacterial exacerbations of chronic bronchitis. J Antimicrob Chemother 1997; 40: 63–72PubMedCrossRefGoogle Scholar
  13. 13.
    Chodosh S, Lakshminarayan S, Swarz H, et al. Efficacy and safety of a 10-day course of 400 or 600 milligrams of grepafloxacin once daily for treatment of acute bacterial exacerbations of chronic bronchitis: comparison with a 10-day course of 500 milligrams of ciprofloxacin twice daily. Antimicrob Agents Chemother 1998; 42: 114–20PubMedCrossRefGoogle Scholar
  14. 14.
    Springsklee M, Reiter C, Meyer JM. Safety and tolerability profile of moxifloxacin (MXF) [abstract P208]. 9th European Congress of Clinical Microbiology and Infectious Diseases; 1999 Mar 21-24: Berlin. Clin Microbiol Infect 1999: 140Google Scholar
  15. 15.
    Bowie WR, Willetts V, Jewesson PJ. Adverse reactions in a dose-ranging study with a new long-acting fluoroquinolone, fleroxacin. Antimicrob Agents Chemother 1989; 33: 1778–82PubMedCrossRefGoogle Scholar
  16. 16.
    Vincent J, Agin M, Laboy-Goral L, et al. Effect of dosing with food and bedtime dosing on the incidence of dizziness/lightheadedness with trovafloxacin in young, healthy, female subjects. Proceedings of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998; Sep 24-27; San Diego, California. Washington DC: American Society for Microbiology, 1998; A–086Google Scholar
  17. 17.
    Akahane K, Sekiguchi M, Une T, et al. Structure-epileptogenicity relationship of quinolones with special reference to their interaction with gamma-aminobutyric acid receptor sites. Antimicrob Agents Chemother 1989; 33: 1704–8PubMedCrossRefGoogle Scholar
  18. 18.
    Takayama S, Hirohashi M, Kato M, et al. Toxicity of quinolone antimicrobial agents. J Toxicol Environ Health 1995; 45: 1–45PubMedCrossRefGoogle Scholar
  19. 19.
    von Keutz E, Schlüter G. Preclinical safety evaluation of moxifloxacin, a novel fluoroquinolone. J Antimicrob Chemother 1999; 43 Suppl. B: 91–100CrossRefGoogle Scholar
  20. 20.
    Schmuck G, Schürmann A, Schlüter G. Determination of the excitatory potencies of fluoroquinolones in the central nervous system by an in vitro model. Antimicrob Agents Chemother 1998; 42: 1831–6PubMedGoogle Scholar
  21. 21.
    de Sarro G, Nava F, Calapai G, et al. Effects of some excitatory amino acid antagonists and drugs enhancing γ-aminobutyric acid neurotransmission on pefloxacin-induced seizures in DBA/2 mice. Antimicrob Agents Chemother 1997; 41: 427–34PubMedGoogle Scholar
  22. 22.
    Nakamura M, Abe S, Goto Y, et al. In vivo assessment of prevention of white-noise-induced seizure in magnesium-deficient rats by N-methyl-D-aspartate receptor blockers. Epilepsy Res 1994; 17: 249–56PubMedCrossRefGoogle Scholar
  23. 23.
    Reinhart RA. Magnesium metabolism. A review with special reference to the relationship between intracellular content and serum levels. Arch Intern Med 1988; 148: 2415–20Google Scholar
  24. 24.
    Rhone Poulenc Rorer. Sparfloxacin monograph, Auckland: ADIS International, 1994Google Scholar
  25. 25.
    Domagala JM. Structure-activity and structure-side-effect relationship for the quinolone antibacterials. J Antimicrob Chemother 1994; 33: 685–706PubMedCrossRefGoogle Scholar
  26. 26.
    Schwabe R, Lozo E, Baumann-Wilschke I, et al. Chondrotoxicity and target tissue kinetics of ofloxacin in immature rats after multiple doses. Drugs 1999; 58 Suppl. 2: 385–7CrossRefGoogle Scholar
  27. 27.
    Förster C, Kociok K, Shakibaei M, et al. Quinolone-induced cartilage lesions are not reversible in rats. Arch Toxicol 1996; 70: 474–81PubMedCrossRefGoogle Scholar
  28. 28.
    Hampel B, Hullmann R, Schmidt H. Ciprofloxacin in pediatrics: worldwide clinical experience based on compassionate use -safety report. Pediatr Infect Dis J 1997; 16: 127–9PubMedCrossRefGoogle Scholar
  29. 29.
    Pertuiset E, Lenoir G, Jehanne M, et al. Tolerance articulaire de la pefloxacine et de l’ofloxacine chez les enfants et adolescents atteints de mucoviscidose. Rev Rheumat 1989; 56: 735–40Google Scholar
  30. 30.
    Stahlmann R, Lode H. Safety of quinolones [letter]. Lancet 1998; 352(9136): 1313PubMedCrossRefGoogle Scholar
  31. 31.
    Syllm-Rapoport I, Strassburger I, Grüneberg D, et al. Über den experimentellen Magnesium-Mangel beim Hund. Acta Biol Med Germ 1958; 1: 141–63PubMedGoogle Scholar
  32. 32.
    Stahlmann R, Förster C, Shakibaei M, et al. Magnesium deficiency induces joint cartilage lesions in juvenile rats which are identical with quinolone-induced arthropathy. Antimicrob Agents Chemother 1995; 39: 2013–8PubMedCrossRefGoogle Scholar
  33. 33.
    Hayem G, Petit PX, Levacher M, et al. Cytofluorometric analysis of chondrotoxicity of fluoroquinolone antimicrobial agents. Antimicrob Agents Chemother 1994; 38: 243–7PubMedCrossRefGoogle Scholar
  34. 34.
    Stahlmann R, Schwabe R, Pfister K, et al. Supplementation with magnesium and tocopherol diminishes quinolone-induced chondrotoxicity in immature rats. Drugs 1999; 58 Suppl. 2: 393–4CrossRefGoogle Scholar
  35. 35.
    Kahn MF, Hayem G. Tendons and fluoroquinolones -unresolved issues. Rev Rhum Engl Ed 1997; 64: 437–9PubMedGoogle Scholar
  36. 36.
    Pierfitte C, Royer RJ. Tendon disorders with fluoroquinolones. Therapie 1996; 51: 419–20PubMedGoogle Scholar
  37. 37.
    Shakibaei M, Pfister K, Schwabe R, et al. Effects of ofloxacin on the ultrastructure of Achilles tendon in rats. Drugs 1999; 58 Suppl. 2: 390–2CrossRefGoogle Scholar

Copyright information

© Adis International Limited 1999

Authors and Affiliations

  • Ralf Stahlmann
    • 1
  • Hartmut Lode
    • 2
  1. 1.Institute of Clinical Pharmacology and Toxicology, Department of Toxicology, Benjamin Franklin Medical CenterFreie Universität BerlinBerlinGermany
  2. 2.Hospital Zehlendorf, Heckeshorn, Department of Chest and Infectious Diseasesafil. Freie Universität BerlinBerlinGermany

Personalised recommendations